Serina Therapeutics Inc (SER) - Net Assets
Based on the latest financial reports, Serina Therapeutics Inc (SER) has net assets worth $1.59 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.41 Million) and total liabilities ($10.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Serina Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.59 Million |
| % of Total Assets | 12.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 130.92 |
Serina Therapeutics Inc - Net Assets Trend (2016–2024)
This chart illustrates how Serina Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore SER total assets for the complete picture of this company's asset base.
Annual Net Assets for Serina Therapeutics Inc (2016–2024)
The table below shows the annual net assets of Serina Therapeutics Inc from 2016 to 2024. For live valuation and market cap data, see market cap of Serina Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $508.00K | +101.57% |
| 2023-12-31 | $-32.29 Million | -86.51% |
| 2022-12-31 | $-17.32 Million | -45.81% |
| 2021-12-31 | $-11.88 Million | -120.07% |
| 2020-12-31 | $-5.40 Million | -306.19% |
| 2019-12-31 | $2.62 Million | -68.21% |
| 2018-12-31 | $8.23 Million | -1.06% |
| 2017-12-31 | $8.32 Million | +137.18% |
| 2016-12-31 | $-22.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Serina Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1565400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.16% |
| Other Components | $44.96 Million | 7013.73% |
| Total Equity | $641.00K | 100.00% |
Serina Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Serina Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HG Capital Trust PLC
LSE:HGT
|
$17.80 Million |
|
Aqua Corporation Public Company Limited
BK:AQUA
|
$17.81 Million |
|
Drillcon AB
ST:DRIL
|
$17.81 Million |
|
Penpower Technology Ltd
TWO:5211
|
$17.81 Million |
|
Matichon Public Company Limited
BK:MATI
|
$17.79 Million |
|
Diversified Gateway Solutions Bhd
KLSE:0131
|
$17.79 Million |
|
AztechWB Co. Ltd
KQ:032080
|
$17.78 Million |
|
Sycal Ventures Bhd
KLSE:9717
|
$17.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Serina Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -32,294,000 to 641,000, a change of 32,935,000.
- Net loss of 11,141,000 reduced equity.
- Share repurchases of 10,000,000 reduced equity.
- New share issuances of 5,000,000 increased equity.
- Other factors increased equity by 49,076,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.14 Million | -1738.07% |
| Share Repurchases | $10.00 Million | -1560.06% |
| Share Issuances | $5.00 Million | +780.03% |
| Other Changes | $49.08 Million | +7656.16% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Serina Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-22.99 | $1.89 | x |
| 2017-12-31 | $7.15 | $1.89 | x |
| 2018-12-31 | $7.50 | $1.89 | x |
| 2019-12-31 | $2.09 | $1.89 | x |
| 2020-12-31 | $-4.78 | $1.89 | x |
| 2021-12-31 | $-10.98 | $1.89 | x |
| 2022-12-31 | $-15.95 | $1.89 | x |
| 2023-12-31 | $-3.84 | $1.89 | x |
| 2024-12-31 | $0.09 | $1.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Serina Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1738.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19894.64%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 10.49x
- Recent ROE (-1738.07%) is below the historical average (-275.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -929.89% | 0.52x | 0.00x | $-13.15 Million |
| 2017 | -90.38% | -468.66% | 0.15x | 1.32x | $-7.31 Million |
| 2018 | -100.74% | -537.39% | 0.13x | 1.43x | $-8.25 Million |
| 2019 | -547.97% | -703.36% | 0.23x | 3.36x | $-12.38 Million |
| 2020 | 0.00% | -20120.37% | 0.01x | 0.00x | $-10.35 Million |
| 2021 | 0.00% | -41.61% | 0.96x | 0.00x | $-81.50K |
| 2022 | 0.00% | -536.42% | 0.15x | 0.00x | $-960.91K |
| 2023 | 0.00% | 167.11% | 0.35x | 0.00x | $8.50 Million |
| 2024 | -1738.07% | -19894.64% | 0.01x | 10.49x | $-11.21 Million |
Industry Comparison
This section compares Serina Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,374,297
- Average return on equity (ROE) among peers: -386.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Serina Therapeutics Inc (SER) | $1.59 Million | 0.00% | 6.79x | $17.80 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.20 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.57 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $313.99 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.85 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $793.56 Million |
| Arbutus Biopharma Corp (ABUS) | $26.88 Million | -30.41% | 0.07x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $3.65 Billion |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more